

**Rational design of Galactopyranoside-substituted *N*-heterocyclic carbene Palladium(II)
Complexes. Stable and Efficient catalyst for C-C coupling in aqueous medium**

Ariana W. Hobsteter, Marcos J. Lo Fiego^{†,*} and Gustavo F. Silbestri^{†,*}

INQUISUR, Departamento de Química, Universidad Nacional del Sur (UNS)-CONICET, Av. Alem 1253, B8000CPB
Bahía Blanca, Argentina.

* Corresponding authors: marcos.lofiego@uns.edu.ar (M. J. Lo Fiego); gsilbestri@uns.edu.ar (G. F. Silbestri)


† Member of CONICET

Supplementary Material


Table of Contents

¹ H and ¹³ C NMR of 3a	S2
HSQC and FTIR-neat of 3a	S3
¹ H and ¹³ C NMR of 3b	S4
HSQC and FTIR-neat of 3b	S5
¹ H and ¹³ C NMR of 3c	S6
HSQC and FTIR-neat of 3c	S7
¹ H and ¹³ C NMR of 4a	S8
HSQC of 4a	S9
¹ H and ¹³ C NMR of <i>o</i>-methoxybiphenyl	S10
¹ H and ¹³ C NMR of <i>m</i>-methoxybiphenyl	S11
¹ H and ¹³ C NMR of <i>p</i>-methoxybiphenyl	S12
¹ H and ¹³ C NMR of <i>m</i>-methylbiphenyl	S13
¹ H and ¹³ C NMR of <i>p</i>-methylbiphenyl	S14
¹ H and ¹³ C NMR of <i>m</i>-chlorobiphenyl	S15
¹ H and ¹³ C NMR of <i>p</i>-cyanobiphenyl	S16


1-Butyl-3-(2,3,4,6-tetra-O-acetyl- β -D-galactopyranosyl)imidazol-2-ylidene dichloro (3a, ^1H NMR, CDCl_3)




1-Butyl-3-(2,3,4,6-tetra-O-acetyl- β -D-galactopyranosyl)imidazol-2-ylidene dichloro (3a, ^{13}C NMR, CDCl_3)




1-Butyl-3-(2,3,4,6-tetra-O-acetyl- β -D-galactopyranosyl)imidazol-2-ylidene dichloro (3a, HSQC, CDCl₃)




1-Butyl-3-(2,3,4,6-tetra-O-acetyl- β -D-galactopyranosyl)imidazol-2-ylidene dichloro (3a, FTIR-neat)




1-Mesityl-3-(2,3,4,6-tetra-O-acetyl- β -D-galactopyranosyl)imidazol-2-ylidene dichloro (3b, ^1H NMR, CDCl_3)




1-Mesityl-3-(2,3,4,6-tetra-O-acetyl- β -D-galactopyranosyl)imidazol-2-ylidene dichloro (3b, ^{13}C NMR, CDCl_3)




1-Mesityl-3-(2,3,4,6-tetra-O-acetyl- β -D-galactopyranosyl)imidazol-2-ylidene palladium(II) pyridine dichloro (3b, HSQC, CDCl₃)




1-Mesityl-3-(2,3,4,6-tetra-O-acetyl- β -D-galactopyranosyl)imidazol-2-ylidene palladium(II) pyridine dichloro (3b, FTIR-neat)




1-(2,3,4,6-Tetra-O-acetyl- β -D-galactopyranosyl)-3-(2,3,4,6-tetra-O-acetyl- β -D-galactopyranosyl) imidazol-2-ylidene palladium(II) pyridine dichloro (3c, ^1H NMR, CDCl_3)




1-(2,3,4,6-Tetra-O-acetyl- β -D-galactopyranosyl)-3-(2,3,4,6-tetra-O-acetyl- β -D-galactopyranosyl) imidazol-2-ylidene palladium(II) pyridine dichloro (3c, ^{13}C NMR, CDCl_3)




1-(2,3,4,6-Tetra-O-acetyl- β -D-galactopyranosyl)-3-(2,3,4,6-tetra-O-acetyl- β -D-galactopyranosyl) imidazol-2-ylidene palladium(II) pyridine dichloro (3c, HSQC, CDCl₃)




1-(2,3,4,6-Tetra-O-acetyl- β -D-galactopyranosyl)-3-(2,3,4,6-tetra-O-acetyl- β -D-galactopyranosyl) imidazol-2-ylidene palladium(II) pyridine dichloro (3c, FTIR-neat)




1-Butyl-3-(β -D-galactopyranosyl)imidazol-2-ylidene palladium(II) pyridine dichloro (4a, ^1H NMR, CDCl_3)




1-Butyl-3-(β -D-galactopyranosyl)imidazol-2-ylidene palladium(II) pyridine dichloro (4a, ^{13}C NMR, CDCl_3)




1-Butyl-3-(β -D-galactopyranosyl)imidazol-2-ylidene palladium(II) pyridine dichloro (4a**, HSQC, CDCl_3)**




o-methoxybiphenyl (^1H NMR, CDCl_3)




o-methoxybiphenyl (^{13}C NMR, CDCl_3)




m-methoxybiphenyl (^1H NMR, CDCl_3)




m-methoxybiphenyl (^{13}C NMR, CDCl_3)




p-methoxybiphenyl (^1H NMR, CDCl_3)




p-methoxybiphenyl (^{13}C NMR, CDCl_3)




***m*-methylbiphenyl (^1H NMR, CDCl_3)**




***m*-methylbiphenyl (^{13}C NMR, CDCl_3)**




p-methylbiphenyl (^1H NMR, CDCl_3)




p-methylbiphenyl (^{13}C NMR, CDCl_3)




m-chlorobiphenyl (^1H NMR, CDCl_3)



m-chlorobiphenyl (^{13}C NMR, CDCl_3)



p-cyanobiphenyl (^1H NMR, CDCl_3)



p-cyanobiphenyl (^{13}C NMR, CDCl_3)

